Apabila kanser hati primer dikaitkan dengan asites, jaundis, metastasis jauh, dsb., ia dipanggil kanser hati primer lanjutan. Rawatan kanser hati primer lanjutan adalah sukar, dan kesan rawatan klinikal tidak sesuai. Pembedahan bukanlah satu pilihan untuk merawat kanser hati peringkat lanjut kerana ia telah merebak ke nodus limfa atau organ lain.
If the liver is in good condition (Child-Pugh grade A or B), the doctor will consider treatment with the targeted therapeutic drugs Sorafenib (Nexavar) or Lenvama (Lenvima). Growth can prolong the survival time of patients. If the patient develops drug resistance, the targeted drug repaglinide (Stivarga) or the imunoterapi drug nivolumab (Opdivo) can be used instead.
In addition, keeping an eye on clinical trial information at any time and actively participating in relevant clinical trials such as chemotherapy, radiotherapy, and immunotherapy may also bring opportunities and hope for patients with advanced kanser hati. It is hoped that in the next few years, researchers will make a huge breakthrough in the field of liver cancer diagnosis and treatment.
